Evidence map›Paper›PMID 41203806›Full record

ArticleScientific reports2025

Network toxicology, transcriptomics, and cytotoxic validation reveal TDCPP-induced pterygium mechanisms.

Ji Yang, Jiajie Li, Boyu Liang, Nishan Zhao, Peng Zhang, ChengYan Fang, Tao Xie, Ping Xiang, Hai Liu

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ji Yang *Department of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China.
Jiajie Li *Department of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China.
Boyu Liang *Department of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China.
Nishan Zhao *Department of Pathology, Affiliated Hospital of Yunnan University, Kunming, China.
Peng ZhangDepartment of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China.
ChengYan FangDepartment of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China.
Tao XieDepartment of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China.
Ping XiangInstitute of Environmental Remediation and Human Health, School of Ecology and Environment, Southwest Forestry University, Kunming, China. xiangping@swfu.edu.cn.
Hai LiuDepartment of Ophthalmology, The Eye Disease Clinical Medical Research Center of Yunnan Province, the Eye Disease Clinical Medical Center of Yunnan Province, The Second People's Hospital of Yunnan Province, Affiliated Hospital of Yunnan University, Kunming, China. herryhai@ynu.edu.cn.

Funding

Key Project of the Provincial Clinical Medical Center of Yunnan Province 2024YNLCYXZX0343National Clinical Key Specialty Ophthalmology Open Foundation ZKF2024041National Clinical Key Specialty Ophthalmology Open Foundation ZKF2024042National Natural Science Foundation of China 82460201Yunnan University Medical Research Foundation YDYXJJ2024-0003Yunnan Xingdian Youth Talent Program XDYC-MY-2024Yunnan Xingdian Youth Talent Program YNQR-QNRC-2018-049Yunnan Young and middle-aged Academic and Technical Leader Project 202205AC160016
6 · The paper itself

Abstract

Pterygium, a common ocular surface disorder, is associated with environmental factors such as ultraviolet exposure and air pollution. Tris(1,3-dichloro-2-propyl) phosphate (TDCPP), a widely used organophosphate flame retardant, has been detected in environmental and biological samples, yet its role in pterygium pathogenesis remains unclear. This study employed an integrative approach combining network toxicology, transcriptome sequencing, and in vitro cytotoxicity assays to elucidate the molecular mechanisms linking TDCPP exposure to pterygium development. Bioinformatics analysis identified 273 TDCPP-related targets and 1,078 pterygium-associated genes, with 43 overlapping candidates. Weighted gene co-expression network analysis (WGCNA) revealed two key modules correlated with pterygium phenotypes, highlighting MMP3 as a central regulator. Molecular docking and dynamics simulations confirmed stable interactions between TDCPP and MMP3 (binding energy: -5.9 kcal/mol), supported by RMSD, RMSF, and hydrogen bonding analyses. In vitro experiments demonstrated that low-dose TDCPP (0.5 µM) upregulated MMP3 expression in immortalized human conjunctival fibroblasts, enhancing cell proliferation, while higher concentrations (50 µM) induced cytotoxicity. These findings suggest that TDCPP promotes pterygium pathogenesis via MMP3-mediated extracellular matrix remodeling and fibroblast proliferation. This study provides novel insights into the environmental etiology of pterygium and identifies MMP3 as a potential therapeutic target for TDCPP-associated ocular surface disorders.

Indexed as

Organophosphorus CompoundsPterygiumTranscriptomeCell ProliferationComputational BiologyFibroblastsGene Expression ProfilingGene Regulatory NetworksHumansMatrix Metalloproteinase 3Molecular Docking SimulationMatrix Metalloproteinase 3MMP3 protein, humanOrganophosphorus CompoundsCytotoxicityMMP3Network toxicologyPterygiumTDCPPTranscriptomics

Identifiers

PMID41203806
PMCPMC12595063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.